Debate over compounding bill centers on supplier verification, patient safety and access

HB 2,613 would require tighter quality-assurance measures for compounded drugs; drugmakers and patient‑safety groups urged safeguards targeting high‑volume, mass‑marketed compounded GLP‑1 products, while pharmacists, hospitals and community clinics warned the bill as written would overreach, raise costs, delay care and risk limiting essential patient‑specific compounding.